SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: 3D illustration of stem cells used for cell therapy
Cell therapy
Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD
The approval concludes what has been a difficult regulatory path for Ryoncil, which suffered FDA rejections in 2020 and 2023.
December 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: WHO headquarters in Geneva, Switzerland/
GLP-1
GLP-1s Potentially ‘Transformative’ but Could Lead to ‘Distorted’ Obesity Care: WHO
According to the World Health Organization, GLP-1 receptor agonists are currently being used in a highly medicalized manner. Healthcare systems need to enact more holistic solutions, focusing on health promotion, disease prevention and policy interventions.
December 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Businessman makes employee cuts as part of layoff
Layoffs
The 5 Largest Biopharma Layoffs of 2024
While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees in 2024.
December 19, 2024
 · 
7 min read
 · 
Angela Gabriel
Facade of Novo Nordisk's office in Fremont, California
GLP-1
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.
December 18, 2024
 · 
2 min read
 · 
Annalee Armstrong
Novo Nordisk advertising flags and logo on facade
Deals
Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab
Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.
December 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Year 2024 on a sheet of typewriter paper close-up
Editorial
2024: A Year of Cautious IPOs, Restraint and Breakthroughs
BioSpace Senior Editor Annalee Armstrong reflects on the year that was, and what’s to come in 2025.
December 18, 2024
 · 
2 min read
 · 
Annalee Armstrong
Sketch of people teamwork, gears, production. Doodle cartoon mechanism with machinery and cogwheels. Hand drawn vector illustration for business and industry design isolated on white.
Manufacturing
Biopharma’s Big Question of 2024: Can You Scale It?
Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.
December 18, 2024
 · 
5 min read
 · 
Annalee Armstrong
machete with tip in ground outdoors
Opinion
Lessons From Humira on How to Tackle Unjust Extensions of Drug Monopolies With Policy
AbbVie’s blockbuster Humira held 105 patents, shielding the anti-inflammatory drug from biosimilar competition for more than 20 years. Proposed reforms could help prevent companies from extending exclusivity with such patent thickets.
December 18, 2024
 · 
4 min read
 · 
Timothy Bonis
South San Francisco, CA, USA - May 1, 2022: Exterior view of the Merck Researches Laboratories in South San Francisco, California. Merck & Co., Inc. is a global pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada.
GLP-1
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.
December 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS